Commentary on Abstracts #3153, #3592, #3168, #3170, #704, #2214, #3275, #1086, #2560, and #3264

Publication
Article
OncologyONCOLOGY Vol 15 No 2
Volume 15
Issue 2

Rituximab is also being explored in other lymphoid malignancies. Some of the most interesting data are in patients with CD20-positive Hodgkin’s disease (abstract #3153). The Stanford group (abstract #3592) reported on 13 patients. Of the 9

Rituximab is also being explored in other lymphoid malignancies. Some of the most interesting data are in patients with CD20-positive Hodgkin’s disease (abstract #3153). The Stanford group (abstract #3592) reported on 13 patients. Of the 9 who were assessable for response, there were 6 CRs and 3 PRs with a single relapse at 6 months. The German Hodgkin’s group reported on 6 patients, all of whom had failed at least one prior treatment regimen. Of the 5 with lymphocyte-predominant Hodgkin’s disease, there were 4 CRs and 1 PR; the patient with classical Hodgkin’s disease also attained a CR. Lower response rates appear to be achievable in patients with classical Hodgkin’s disease (abstract #3168), with 1 CR and 2 PRs in 18 patients with nodular sclerosis histology, 13 of whom had progressed after stem cell transplantation. Clearly, this agent should be studied as part of a multidrug regimen in the treatment of this disease.

Coiffier et al (Blood 92:1927-1932, 1998) have previously demonstrated activity for rituximab in patients with mantle cell lymphoma, although responses were brief without further therapy. Romaguera et al (abstract #3170) added the antibody to their effective hyper CVAD (cyclophosphamide, vincristine, doxorubicin [Adriamycin], dexamethasone) regimen (Khouri et al: J Clin Oncol 16:3803-3809, 1998) and presented their data from an ongoing trial in 43 patients. The CR rate was 90%, but longer follow-up is needed to assess the durability of responses in this population. Treon et al (abstract #704) treated 19 multiple myeloma patients whose bone marrow cells were CD20 positive, with a single partial response.

Using the standard dose and schedule of administration, rituximab has exhibited relatively limited single-agent activity in small lymphocytic lymphoma/chronic lymphocytic leukemia (Piro et al: Proc Am Soc Clin Oncol 18:14a[abstract #49], 1999; Nguyen et al: Eur J Haematol 62:76-82, 1999; Maloney et al: Blood 90:2188-2195, 1997). Nevertheless, in vitro and early clinical data suggest the potential for the antibody to sensitize lymphoma cells to the effects of chemotherapy. As a result, rituximab is being incorporated into multiagent regimens with promising results.

Keating et al (abstract #2214) built on their prior institutional experience using the combination of fludarabine and cyclophosphamide (O’Brien et al: Int J Hematol 64:S56[abstract #214], 1996) by adding rituximab. Of the 35 patients evaluable after six courses, there were 57% CRs and a response rate of 94%; for those who had completed only three courses, responses occurred in 81%, with 14% CRs. Major infections were uncommon (3%), with no opportunistic organisms. Impressive data were also reported for patients with previously treated chronic lymphocytic leukemia using this same regimen (abstract #3275).

Based on its B-cell-depleting properties, rituximab as a single agent or in combination with immunosuppressive chemotherapy drugs has been used to treat nonmalignant conditions such as immune thrombocytopenic purpura and autoimmune hemolytic anemia (Hegde et al: Proc Am Soc Clin Oncol [in press], 2001; Perrota and Abuel: Blood 92:88b[abstract #3360], 1998; abstracts #1086, #2560, #3264), with encouraging success in many patients who failed conventional therapies.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers